Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

被引：59

作者：

Marin, D ^{[1
]}

Goldman, JM ^{[1
]}

Olavarria, E ^{[1
]}

Apperley, JF ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London W12 0NN, England

来源：

BLOOD | 2003年 / 102卷 / 07期

关键词：

D O I：

10.1182/blood-2003-06-2042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2702 / 2703

页数：2

共 5 条

[1] Management decisions in chronic myeloid leukemia [J].

Goldman, JA ;

Marin, D .

SEMINARS IN HEMATOLOGY, 2003, 40 (01) :97-103

[2] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[3] Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia [J].

Kantarjian, HM ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Garcia-Manero, G ;

Faderl, S ;

Thomas, D ;

Shan, JQ ;

Rios, MB ;

Cortes, J .

BLOOD, 2003, 101 (02) :473-475

[4] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[5]

Zonder JA, 2003, CLIN CANCER RES, V9, P2092

← 1 →